Jefferies analyst Andrew Tsai raised the firm’s price target on Praxis Precision (PRAX) to $300 from $65 and keeps a Buy rating on the shares. The firm expects “significant stock upside” following ulixacaltamide’s Phase 3 Essential3 program success in essential tremor, which it sees as a $2.5B-plus opportunity. The firm, which sees the data enabling Praxis to submit an NDA in early 2026, sees 70% odds of success for approval.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Praxis Precision price target raised to $350 from $155 at Guggenheim
- Why Is Praxis Precision Medicines (PRAX) Stock Up 155% Today?
- Praxis Precision Medicines Announces Positive Phase 3 Results
- Praxis Precision announces results from two Phase 3 studies of ulixacaltamide
- 3 Best Stocks to Buy Now, 9/22/2025, According to Top Analysts